Alex DePaoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alex DePaoli has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Alan Kutach
NGM Biopharmaceuticals, South San Francisco, CA 94080, USA
2 shared publicationsAnna Chen
NGM Biopharmaceuticals, South San Francisco, CA 94080, USA
2 shared publicationsAvantika Kekatpure
NGM Biopharmaceuticals, South San Francisco, CA 94080, USA
2 shared publicationsBenbo Song
NGM Biopharmaceuticals, South San Francisco, CA 94080, USA
2 shared publicationsBethany Winans
NGM Biopharmaceuticals, South San Francisco, CA 94080, USA
2 shared publicationsDaniel D. Kaplan
NGM Biopharmaceuticals, South San Francisco, CA 94080, USA
2 shared publications
Latest Publications
- Open Access
- 31 May 2022
- Published by Elsevier in Cell Reports
- Vol. 39 (9) , 110872
Glucagon-receptor-antagonism-mediated β-cell regeneration as an effective anti-diabetic therapy
- 31 May 2022
- Published by Elsevier in Cell Reports
- Vol. 39 (9) , 110872
Open AccessGlucagon-receptor-antagonism-mediated β-cell regeneration as an effective anti-diabetic therapy
- 1 September 2021
- Published by Elsevier in Annals of Oncology
- Vol. 32, S610-S611
550P Initial results of a phase Ia/Ib study of NGM120, a first-in-class anti-GDNF family receptor alpha like (GFRAL) antibody in patients (pts) with advanced solid tumors
- 1 September 2021
- Published by Elsevier in Annals of Oncology
- Vol. 32, S610-S611
550P Initial results of a phase Ia/Ib study of NGM120, a first-in-class anti-GDNF family receptor alpha like (GFRAL) antibody in patients (pts) with advanced solid tumors
- Open Access
- 1 January 2021
- Published by Elsevier in SSRN Electronic Journal
Glucagon Receptor Antagonism-Mediated β-Cell Regeneration as an Effective Anti-Diabetic Therapy
Type 1 Diabetes (T1D) is a chronic disease with potentially severe complications, and β-cell deficiency underlies this disease. Despite active research, no therapy to date has been able to induce β-cell regeneration in humans. Here, we discovered the β-cell regenerative effects of glucagon receptor antibodies (anti-GcgR). Treatment with anti-GcgR in mouse models of β-cell deficiency leads to reversal of hyperglycemia, increased plasma insulin and C-peptide levels, and restored β-cell mass. We demonstrate that both β-cell proliferation and α- to β-cell transdifferentiation contribute to anti-GcgR-induced β-cell regeneration. Interestingly, anti-GcgR-induced α-cell hyperplasia can be uncoupled from β-cell regeneration with treatment cessation and antibody elimination from the body. Importantly, we are able to show that anti-GcgR induced α- to β-cell transdifferentiation is also observed in non-human primates. Furthermore, anti-GcgR and anti-CD3 combination therapy reverses diabetes and increases β-cell mass in the non-obese diabetic (NOD) mouse model of T1D. Taken together, our novel findings suggest that the combination of anti-GcgR with an immune modulator may be an effective therapy for T1D.
- 1 January 2021
- Published by Elsevier in SSRN Electronic Journal
Open AccessGlucagon Receptor Antagonism-Mediated β-Cell Regeneration as an Effective Anti-Diabetic Therapy
Type 1 Diabetes (T1D) is a chronic disease with potentially severe complications, and β-cell deficiency underlies this disease. Despite active research, no therapy to date has been able to induce β-cell regeneration in humans. Here, we discovered the β-cell regenerative effects of glucagon receptor antibodies (anti-GcgR). Treatment with anti-GcgR in mouse models of β-cell deficiency leads to reversal of hyperglycemia, increased plasma insulin and C-peptide levels, and restored β-cell mass. We demonstrate that both β-cell proliferation and α- to β-cell transdifferentiation contribute to anti-GcgR-induced β-cell regeneration. Interestingly, anti-GcgR-induced α-cell hyperplasia can be uncoupled from β-cell regeneration with treatment cessation and antibody elimination from the body. Importantly, we are able to show that anti-GcgR induced α- to β-cell transdifferentiation is also observed in non-human primates. Furthermore, anti-GcgR and anti-CD3 combination therapy reverses diabetes and increases β-cell mass in the non-obese diabetic (NOD) mouse model of T1D. Taken together, our novel findings suggest that the combination of anti-GcgR with an immune modulator may be an effective therapy for T1D.
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S430
Serum cholesterol changes associated with NGM282 treatment in obese insulin resistant cynomolgus monkeys are reversed with either a statin or a PCSK9 inhibitor
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S430
Serum cholesterol changes associated with NGM282 treatment in obese insulin resistant cynomolgus monkeys are reversed with either a statin or a PCSK9 inhibitor